CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication.

The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal

Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours.

BC Cancer Benefit Drug List

The BC Cancer Protocol Summary for Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours

BC Cancer Protocol Summary